SEARCH

SEARCH BY CITATION

References

  • 1
    Kim TW,Hung CF,Boyd DA,He L,Lin CT,Kaiserman D,Bird PI,Wu TC. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004; 64: 4005.
  • 2
    Kim TW,Hung CF,Ling M,Juang J,He L,Hardwick JM,Kumar S,Wu TC. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003; 112: 10917.
  • 3
    Kim TW,Hung CF,Juang J,He L,Hardwick JM,Wu TC. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther 2004; 11: 33642.
  • 4
    Chen CH,Wang TL,Hung CF,Yang Y,Young RA,Pardoll DM,Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60: 103542.
  • 5
    Donnelly JJ,Ulmer JB,Shiver JW,Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 61748.
  • 6
    Pardoll DM,Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 1995; 3: 1659.
  • 7
    Germain RN. Antigen processing and presentation. AIDS Res Hum Retroviruses 1992; 8: 76976.
  • 8
    Rosenberg SA,Yang JC,Sherry RM,Hwu P,Topalian SL,Schwartzentruber DJ,Restifo NP,Haworth LR,Seipp CA,Freezer LJ,Morton KE,Mavroukakis SA, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003; 14: 70914.
  • 9
    Wang R,Doolan DL,Le TP,Hedstrom RC,Coonan KM,Charoenvit Y,Jones TR,Hobart P,Margalith M,Ng J,Weiss WR,Sedegah M, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 47680.
  • 10
    Weber R,Bossart W,Cone R,Luethy R,Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. Eur J Clin Microbiol Infect Dis 2001; 20: 8003.
  • 11
    Donnelly J,Berry K,Ulmer JB. Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 2003; 33: 45767.
  • 12
    Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002; 43: 1188200.
  • 13
    De La Vieja A,Dohan O,Levy O,Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000; 80: 1083105.
  • 14
    Dai G,Levy O,Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 45860.
  • 15
    Spitzweg C,Harrington KJ,Pinke LA,Vile RG,Morris JC. Clinical review 132: the sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001; 86: 332735.
  • 16
    Spitzweg C,Dietz AB,O'Connor MK,Bergert ER,Tindall DJ,Young CY,Morris JC. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001; 8: 152431.
  • 17
    Kang JH,Chung JK,Lee YJ,Shin JH,Jeong JM,Lee DS,Lee MC. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med 2004; 45: 15716.
  • 18
    Spitzweg C,O'Connor MK,Bergert ER,Tindall DJ,Young CY,Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60: 652630.
  • 19
    Chen L,Altmann A,Mier W,Eskerski H,Leotta K,Guo L,Zhu R,Haberkorn U. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006; 47: 85462.
  • 20
    Scholz IV,Cengic N,Baker CH,Harrington KJ,Maletz K,Bergert ER,Vile R,Goke B,Morris JC,Spitzweg C. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005; 12: 27280.
  • 21
    Kakinuma H,Bergert ER,Spitzweg C,Cheville JC,Lieber MM,Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003; 63: 78404.
  • 22
    Ferrone CR,Perales MA,Goldberg SM,Somberg CJ,Hirschhorn-Cymerman D,Gregor PD,Turk MJ,Ramirez-Montagut T,Gold JS,Houghton AN,Wolchok JD. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 2006; 12: 55119.
  • 23
    Zhang W,Dong SF,Sun SH,Wang Y,Li GD,Qu D. Coimmunization with IL-15 plasmid enhances the longevity of CD8 T cells induced by DNA encoding hepatitis B virus core antigen. World J Gastroenterol 2006; 12: 472735.
  • 24
    Kutzler MA,Robinson TM,Chattergoon MA,Choo DK,Choo AY,Choe PY,Ramanathan MP,Parkinson R,Kudchodkar S,Tamura Y,Sidhu M,Roopchand V, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005; 175: 11223.
  • 25
    Schirmbeck R,Riedl P,Kupferschmitt M,Wegenka U,Hauser H,Rice J,Kroger A,Reimann J. Priming protective CD8 T cell immunity by DNA vaccines encoding chimeric, stress protein-capturing tumor-associated antigen. J Immunol 2006; 177: 153442.
  • 26
    Cho JA,Yeo DJ,Son HY,Kim HW,Jung DS,Ko JK,Koh JS,Kim YN,Kim CW. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int J Cancer 2005; 114: 61322.
  • 27
    Cao Y,Karsten U. Binding patterns of 51 monoclonal antibodies to peptide and carbohydrate epitopes of the epithelial mucin (MUC1) on tissue sections of adenolymphomas of the parotid (Warthin's tumours): role of epitope masking by glycans. Histochem Cell Biol 2001; 115: 34956.
  • 28
    Mandell RB,Mandell LZ,Link CJ,Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59: 6618.
  • 29
    Rodriguez F,An LL,Harkins S,Zhang J,Yokoyama M,Widera G,Fuller JT,Kincaid C,Campbell IL,Whitton JL. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 1998; 72: 517481.
  • 30
    Tobery TW,Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997; 185: 90920.
  • 31
    Boyle JS,Brady JL,Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998; 392: 40811.
  • 32
    Biragyn A,Tani K,Grimm MC,Weeks S,Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 2538.
  • 33
    King CA,Spellerberg MB,Zhu D,Rice J,Sahota SS,Thompsett AR,Hamblin TJ,Radl J,Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4: 12816.
  • 34
    Weiss WR,Ishii KJ,Hedstrom RC,Sedegah M,Ichino M,Barnhart K,Klinman DM,Hoffman SL. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998; 161: 232532.
  • 35
    Chow YH,Chiang BL,Lee YL,Chi WK,Lin WC,Chen YT,Tao MH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 13209.
  • 36
    Corr M,Tighe H,Lee D,Dudler J,Trieu M,Brinson DC,Carson DA. Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol 1997; 159: 49995004.
  • 37
    Klinman DM,Yamshchikov G,Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158: 36359.
  • 38
    Lee YJ,Chung JK,Shin JH,Kang JH,Jeong JM,Lee DS,Lee MC. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 2004; 14: 88995.
  • 39
    Gendler S,Taylor-Papadimitriou J,Duhig T,Rothbard J,Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263: 128203.
  • 40
    Gendler SJ,Lancaster CA,Taylor-Papadimitriou J,Duhig T,Peat N,Burchell J,Pemberton L,Lalani EN,Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 1528693.
  • 41
    Snyder LA,Goletz TJ,Gunn GR,Shi FF,Harris MC,Cochlin K, McCauley C,McCarthy SG,Branigan PJ,Knight DM. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 2006; 24: 334052.
  • 42
    Mushenkova N,Moiseeva E,Chaadaeva A,Den Otter W,Svirshchevskaya E. Antitumor effect of double immunization of mice with mucin 1 and its coding DNA. Anticancer Res 2005; 25: 38938.
  • 43
    Fong CL,Mok CL,Hui KM. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression. Gene Ther 2006; 13: 24556.
  • 44
    Kontani K,Taguchi O,Ozaki Y,Hanaoka J,Tezuka N,Sawai S,Inoue S,Fujino S,Maeda T,Itoh Y,Ogasawara K,Sato H, et al. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther 2002; 9: 3307.
  • 45
    Turowska MD,Turowski D,Wysocka J,Rogowski F. The effects of radioiodine therapy on peripheral blood lymphocyte subpopulations in patients with Graves' disease. Preliminary report. Nucl Med Rev Cent East Eur 2002; 5: 358.
  • 46
    Choi Y,Jeon YH,Kang JH,Chung JK,Schmidt M,Kim AC. MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-γ+ T cells and enhances protective antitumor immunity. Int J Cancer 2007; 120: 194250.